China Heparin Industry Report, 2010
  • Dec/2010
  • Hard Copy
  • USD $1,600
  • Pages:63
  • Single User License
    (PDF Unprintable)       
  • USD $1,500
  • Code: JMH002
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,100
  • Hard Copy + Single User License
  • USD $1,800
      
Although it is with rich source of heparin raw materials, China lags behind in the manufacturing technologies for heparin drugs. Chinese heparin industry presents mainly the exportation of heparin API (Active Pharmaceutical Ingredients) and the importation of heparin drugs.

In 2009, China’s heparin API export volume reached 13.4 trillion units, accounting for 47.5% of the world’s total heparin API supply. The overseas markets of China heparin and its salt and the exporting enterprises are relatively concentrated in distribution. During the period from January to October of 2010, the top five export destinations of China’s heparin and its salt were France, Germany, the USA, Austria and Italy, altogether taking 88% of China’s heparin API export value in the same period. In H1 2010, the top four Chinese exporting enterprises of heparin and its salt include Shenzhen Hepalink Pharmaceutical Co., Ltd, Changzhou Qianhong Bio-Pharma Co., Ltd, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, and Yantai Dongcheng Biochemicals Co., Ltd, with a share of 79% in all of China’s heparin API export value in the same period.     

Export Destinations of China Heparin and Its Salt, Jan.-Oct., 2010 (by Value)
 2010121503.gif
Source: ResearchInChina

Heparin drugs, the downstream products of heparin API, are essential antithrombotic drugs. With the explosive population of cardio-cerebrovascular sufferers in China, the market share of heparin drugs keeps increasing year by year. Taking low-molecular weight heparin preparation with a 87.4% share of China’s heparin drugs market (2009) for example, the market size grew at an annual rate of 18% between 2006 and 2009. And in 2009, it touched RMB 1.11 billion.

China Low-Molecular-Weight Heparin Drug Market Size, 2006-2009 (Unit: RMB100M)
 2010121504.gif
Source: Medical Economic News; ResearchInChina

Yet, Chinese market of heparin drugs, in particular the market of low-molecular weight heparin, is dominated by foreign brands on account of technology barriers although China is the world’s key supplier of heparin sodium API.

In terms of low-molecular heparin sodium market, the four foreign brands including France-based Sanofi, America-based Pfizer Pharmaceuticals and Abbott Laboratories, Italy-based ALFA WASSERMANN took a sizable lead of 83.8% market share in 2009. In particular, France-based Sanofi, whose market share accounted for 54.5%, continued to rank the first place. But among the domestic enterprises, Shandong QILU Pharmaceutical takes the lead with the market share no more than 7.4%. In low-molecular heparin calcium market, GlaxoSmithKline topped the list in 2009 with the market share of 59%, far ahead of China-based Hebei Changshan Biochemical Pharmaceutical, runner-up with the market share of 12%.

The report not only analyzes the international operating environment of China heparin industry, the status quo and competition pattern of Chinese heparin API and heparin drug market, but elaborates the operation and development prospect of relatively competitive Chinese manufacturers of heparin API and/or preparations.
1 Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2 International Operating Environment of Heparin Industry
2.1 Demand of Heparin Medicine
2.2 Distribution of Heparin Medicine Demand
2.3 Heparin API Demand
2.4 Overseas Competitors
2.4.1 Organon
2.4.2 SPL
2.4.3 Sanofi-Aventis
2.4.4 GlaxoSmithKline
2.4.5 Pfizer Pharmaceuticals Limited
2.5 Related Policy
2.6 Market Forecast

3Current Development of China Heparin API Industry
3.1 Market Overview
3.2 Demand & Supply
3.3 Competition Pattern
3.4 Dynamics
3.5 Related Policy
3.6 Market Forecast

4 Current Development of China Heparin Preparation Industry
4.1 Overview of Antithrombotic Drugs
4.2 Market Overview
4.3 Demand & Supply
4.4 Competition Pattern
4.5 Dynamics & Patents
4.6 Market Forecast

5 China’s Import & Export of Heparin
5.1 Exporting Trade
5.1.1 Export Quantity and Prices
5.1.2 Export Destinations
5.1.3 Chinese Exporting Enterprises
5.2 Import Trade

6 Heparin Manufacturers in China
6.1 Shenzhen Hepalink Pharmaceutical
6.1.1 Profile
6.1.2 Operation
6.1.3 Dynamics
6.2 Changzhou Qianhong Bio-Pharma 
6.2.1 Profile
6.2.2 Operation
6.2.3 Dynamics
6.3 Nanjing King-Friend Biochemical Pharmaceutical
6.3.1 Profile
6.3.2 Operation
6.4 Yantai Dongcheng Biochemicals
6.4.1 Profile
6.4.2 Operation
6.5 Tianjin Chase Sun Pharmaceutical
6.5.1 Profile
6.5.2 Operation
6.5.3 Dynamics
6.6 Hebei Changshan Biochemical Pharmaceutical 
6.6.1 Profile
6.6.2 Operation
6.6.3 Dynamics
6.7 Wanbang Biopharmaceuticals
6.7.1 Profile
6.7.2 Operation
6.7.3 Dynamics
Heparin Industry Chain
Sales of Heparin Drugs Worldwide, 2003-2012E
Distribution of Heparin Drug Consumption Worldwide, 2009
Distribution of Heparin API Demand Worldwide, 2009
Heparin Sodium Operating Income and Growth of Sanofi-Aventis, 2007-2009
Forecast of Global Heparin Drug Market Development
Heparin API Export Scale of China and Its Percentage in the World Total, 2009
Number of Slaughtered Fattened Hogs (Head) and Year-end Number of Hogs (Head) of China, 2003-2009
Price Trend of Crude Sodium Heparin in China, 2007-2009
World’s Major Manufacturers of Heparin Sodium API, Jan.-Sep., 2009
Heparin Sodium API Supply in China and the World and China’s Share, 2011-2012
China Antithrombotic Drug Market Size and Growth Rate, 2003-2009
Distribution of Three Major Categories of Antithrombotic Drugs in China, Mar., 2009
Proportion of China-made Clopidogrel Sulfate and Ozagrel Products in Antithrombotic Drugs, 2005-2009
Market Shares of Key Anticoagulant Medicines of China, Sep.2008-Sep.2009
Proportion of Lumbrokinase Products of China in Anticoagulant Medicines, 2005-2009
Chinese Market Scale of Heparin Preparation Products, 2009
Proportion of Low-molecular Heparin Calcium and Low-molecular Heparin Sodium in Anticoagulant Medicines of China, 2005-2009
Market Demand for Heparin Sodium Injection Solution in China, 2007-2012
Competition Pattern of China Low-Molecular-Weight Heparin Sodium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Sodium in China, 2009
Competition Pattern of China Low-Molecular-Weight Heparin Calcium Market, 2009
YoY Growth Rate for Sales of Main Competitive Enterprises of Low-molecular Weight Heparin Calcium in China, 2009
Main Patents for Low-Molecular-Weight Heparin
China Low-Molecular-Weight Heparin Drug Market Size, 2006-2014
Export of Key Western Medicines of China, Jan.-Jun. 2009
China’s Export Volume and Price Trend of Heparin Products, 2002-2010
Countries to which China Heparin and Its Salt Get Exported, Jan.-Oct., 2010
Main Chinese Exporting Enterprises of Heparin API and Their Percentages, Jan.-Sep., 2009
Import Volume and Unit Price Trend of Heparin Products in China, 2008-2010 
Destinations of China’s Heparin Product Imports, 2008-2010 
Import Origins of China Heparin Products, 2008-2010 
Heparin Sodium API Operating Income of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007-2009
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd by Product, 2007-2009
Heparin Sodium API Revenue of Shenzhen Hepalink Pharmaceutical Co., Ltd by Region, 2007-2009
Client Distribution of Heparin Sodium API Sales of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007-2009
Total Profit of Shenzhen Hepalink Pharmaceutical Co., Ltd., 2007-2009
Operating Income Structure of Main Products of Changzhou Qianhong Bio-Pharma Co., Ltd, Jan.-Jun., 2010
Sales Revenue of Heparin Sodium API and Injection Solution of Changzhou Qianhong Bio-Pharma Co., Ltd., 2007-2010
Heparin Export Value and Percentage of Changzhou Qianhong Bio-Pharma Co., Ltd., 2007-2009
Top Five Clients of Heparin Sodium API of Changzhou Qianhong Bio-Pharma Co., Ltd, 2009-2010
Operating Income and Total Profit of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, 2007-2008
Heparin API Export of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Jan.-Sep., 2009
Operating Income and Profit of Yantai Dongcheng Biochemicals Co., Ltd, 2007-2008
Heparin API Export of Yantai Dongcheng Biochemicals Co., Ltd, Jan.-Sep., 2009
Operating Income and Net Income of Tianjin Chase Sun Pharmaceutical Co., Ltd., 2007-2010
Operating Income (by Product) of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2009
Heparin Calcium Sales Revenue and YoY Growth of Tianjin Chase Sun Pharmaceutical Co., Ltd, 2007-2009
Gross Margin of Molecular Heparin Calcium of Tianjin Chase Sun Pharmaceutical Co., Ltd., 2007-2009
Operating Income and Profit of Hebei Changshan Biochemical Pharmaceutical Co., Ltd, 2007-2008 
Net Income of Wanbang Biopharmaceuticals, 2007-2010

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统